CME: Expert Perspectives and Best Practice Recommendations for Therapeutic Sequencing in NSCLC Without a Driver Mutation

Improving Clinical Practice in Management of mCRC: A Focus on Tumor Sidedness

Improving Clinical Practice in Management of mCRC: A Focus on Tumor Sidedness
What can the location of a tumor tell you about which treatment option is best for your metastatic colorectal cancer patients?

Available credits: 0.25

Time to complete: 15 Minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Metastatic colorectal cancer is difficult to manage and has multiple genetic mutations, expressions, and amplifications, such as tumor sidedness. And while identifying these distinctions can be challenging, they offer essential clues to which treatment option is best for each patient, as Dr. Scott Kopetz, Dr. Rui-Hua Xu, and Dr. Alberto Sobrero explain.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, The Omnia-Prova Education Collaborative (TOPEC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TOPEC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. 

    Scott Kopetz, MD,PhD, FACP

    Associate Professor
    Department of Gastrointestinal Medical Oncology
    Division of Cancer Medicine
    The University of Texas MD Anderson Cancer Center 
    Houston, TX

    Dr. Kopetz has disclosed he receives consulting fees from Amal Therapeutics, Biocartics, Merck, Navire Pharma, Roche/Genentech, and Symphogen.

    Alberto Sobrero, MD
    Medical Oncology
    IRCCS Ospedale San Martino IST
    Genova, Italy

    Dr. Sobrero has disclosed that he receives consulting fees from Amgen, Bayer, and Sanofi, and is a member of the speaker bureau for Amgen, Bristol-Myers Squidd, Merck, and Roche.

    Rui-Hua Xu, MD
    Director of Sun Yat-sen University Cancer Center
    Guangzhon, China

    Dr. Xu has nothing to disclose.

    Reviewers/Content Planners/Authors:

    • Sean Barrett has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Barry Fiedel, PhD has nothing to disclose.
    • Rob Braun has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Delineate the oncogenic drivers and the role of tumor sidedness in mCRC and their importance in therapy selection
    • Compare existing and evolving guidelines for treatment of mCRC and their role in optimizing treatment strategies 
  • Target Audience

    This activity is designed to meet the educational needs of Oncologists, Oncology Nurses, and Pathologists.

  • Accreditation and Credit Designation Statements

    The Omnia-Prova Education Collaborative, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    The Omnia-Prova Education Collaborative, Inc. designates this enduring material for a maximum of .25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 CreditsTM to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at

  • Provider(s)/Educational Partner(s)

    TOPEC Global designs educational activities based on evidence-based medicine, needs and gaps analyses, learner feedback, and more. Its mission is to serve as an innovative and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.

  • Commercial Support

    This activity is supported by an independent educational grant from Merck KGaA, Darmstadt, Germany.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of TOPEC and TOPEC Global. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of TOPEC Global you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

    Disclaimer: Some products discussed in this activity may not have received regulatory approval by the US FDA for the treatment of patients with colorectal cancer. The FDA has stated that “good medical practice and the best interests of the patient require that physicians use legally available drugs, biologics and devices according to their best knowledge and judgement”.  

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments



We’re glad to see you’re enjoying Global Oncology Academy…
but how about a more personalized experience?

Register for free